Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of <i>Helicobacter pylori</i> Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

Yoon Jin Choi(Colorado School of Public Health), Jae Young Jang(Kyung Hee University), Kwang Hyun Ko(Institut de Recherche Vaccinale), Byoung Kwan Son(Yonsei University), Hang Lak Lee(Hanyang University), Gwang Ho Baik(Hallym University), Jung Mogg Kim(Cleveland Clinic), Hye‐Kyung Jung(Ewha Womans University), Ki‐Nam Shim(Ewha Womans University), Jeong Seop Moon(Inje University Seoul Paik Hospital), Kyoung Oh Kim(Gachon University Gil Medical Center), Hoon Jai Chun(Korea University), Sang Gyun Kim(Seoul National University Hospital), Yong Chan Lee(Yonsei University), Yun Jeong Lim(Dongguk University Ilsan Hospital), Hyunsoo Chung(Seoul National University), Nayoung Kim(Sogang University), Jin Il Kim(Yonsei University), Jie‐Hyun Kim(Kangwon National University), Byung‐Wook Kim(The Catholic University of Korea Incheon St. Mary's Hospital), Hyuk Lee(Yonsei University)
Gut and Liver
July 6, 2022
Cited by 86


Related Papers